Sienna Biopharmaceuticals Announces Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoriasis Trials in Second Half of 2019 -- 27% of subjects achieved 75% reduction in PASI score (PASI 75) vs 13% with vehicle; 29% of subjects achieved two-grade improvement on IGA and ‘clear’ or ‘almost clear’ skin vs 13% with vehicle...

Sienna Biopharmaceuticals Announces Results from First-in-Human Study of SNA-125 in Psoriasis and Continued Progression to Phase 2 -- Phase 1/2 study data of SNA-125 in atopic dermatitis on track to be released in fourth quarter of 2018 -- SNA-125 Phase 2 studies expected to begin in second half of 2019 WESTLAKE VILLAGE,...

Sienna Biopharmaceuticals to Present SNA-125 Pre-Clinical Psoriasis Data as Late-Breaker at the International Investigative Dermatology Congress WESTLAKE VILLAGE, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that pre-clinical data from the Company’s topical product candidate SNA-125,...

Sienna Biopharmaceuticals Announces First Patient Dosed in Proof-of-Concept Trial of Topical by Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis -- Trial to Enroll Approximately 30 Patients with Atopic Dermatitis -- Top-Line Results Expected in Fourth Quarter of 2018 WESTLAKE VILLAGE, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Sienna...

Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125 -- Trial to Enroll Approximately 15 Patients with Psoriasis-- Top-Line Results Expected in Third Quarter of 2018 WESTLAKE VILLAGE, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Sienna...